Financial Status and Intellectual Property - The company's cash balance was approximately $166 million as of December 31, 2021, providing a runway into 2024[6, 9] - The company's IP estate includes patents and patent applications potentially extending into the 2040s[6] - The company anticipates 5-year NCE exclusivity (plus 30 month stay) after approval, in addition to patents[121] Pipeline Programs and Milestones - TERN-201 (VAP-1 Inhibitor) AVIATION Part 1 top-line data is expected in March 2022, and Part 2 top-line data in 2H 2022[8, 14, 113] - TERN-501 (THR-β Agonist) Phase 2a trial is starting in 1H 2022, with top-line data expected in 2H 2023[8] - TERN-601 (Oral GLP-1R Agonist) is engaging in IND-enabling activities, with Phase 1 trial initiation planned for 2023[8, 14, 109] - A combination NASH Phase 2a trial of TERN-101 and TERN-501 is planned to start in 1H 2022[14, 45, 48] TERN-501 (THR-β Agonist) - TERN-501 achieved significant dose-dependent changes in PD markers, including a 166% change in SHBG and a -21% change in LDL-c at the 10 mg dose[31, 32, 34] - TERN-501 exhibits superior selectivity for THR-β over THR-α, with a selectivity ratio of 23, compared to 15 for Resmetirom and 2 for VK2809A[13, 25] TERN-201 (VAP-1 Inhibitor) - TERN-201 is a highly selective inhibitor of VAP-1, with minimal potential to inhibit MAO-A or MAO-B[8, 13, 58, 65] - TERN-201 demonstrated complete inhibition of soluble VAP-1 activity in plasma with all single and multiple doses[68, 70, 71]

For the fiscal year ended December 31, 2021 OR Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39926 Terns Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 98-1448275 (State or other jurisdic ...

g Company Overview NASDAQ: TERN January 2022 2 Forward-Looking Statements This presentation contains forward-looking statements about Terns Pharmaceuticals, Inc. (the "Company," "we," "us," or "our") and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding the Company's strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of manag ...

g Company Overview NASDAQ: TERN November 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about Terns Pharmaceuticals, Inc. (the "Company," "we," "us," or "our") and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding the Company's strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of mana ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39926 Terns Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 98-1448275 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39926 Terns Pharmaceuticals, Inc. Registrant's telephone number, including area code: (650) 525-5535 Securities registered pursuan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39926 Terns Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 98-1448275 ( State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39926 Terns Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 98-1448275 (State or other jurisdic ...